Four marker genes (ID4, SOSTDC1, SLC26A2, TNC) relevant to drug activity to cisplatin on breast cancer cells were derived from the signature genes for breast cancers (Figure 7). This evidence concerns the gene SOSTDC1 and breast carcinoma.